GlassScriptPhysician profile
Isabel Yang Lee
NPI 1033405337
$15,505.81
in general payments reported to CMS, 2019-2025
45 companies · $3,385 in 2025
The $3,385 reported for 2025 was more than what 98% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,269 · 2022: $2,050 · 2023: $3,632 · 2024: $3,170 · 2025: $3,385.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Education: $40.44.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,146.80 |
| Education | $40.44 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $3,956.42 | 2021-2025 | Repatha, Tezspire, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,472.15 | 2021-2024 | Xifaxan, Trulance |
| Glaxosmithkline, LLC. | $1,172.09 | 2021-2025 | Trelegy Ellipta, Nucala, Shingrix |
| Astrazeneca Pharmaceuticals LP | $1,055.44 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Novo Nordisk INC | $687.50 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $667.45 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $663.51 | 2021-2025 | |
| Corcept Therapeutics | $501.23 | 2024-2025 | Korlym |
| Amarin Pharma, INC. | $419.13 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $380.56 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.25 | 2021-2025 | Jardiance |
| Esperion Therapeutics, INC. | $363.15 | 2022-2025 | Nexletol |
| Dexcom, INC. | $357.40 | 2022-2025 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $346.88 | 2021-2023 | Livalo |
| Regeneron Healthcare Solutions, INC. | $282.13 | 2023-2024 | Dupixent |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Isabel Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.